Amerisourcebergen (holding ) Stock News

Wall Street analysts predict that AmerisourceBergen Co. (NYSE:ABC) will post $59.31 billion in sales for the current quarter, Zacks reports. Two analysts have issued estimates for AmerisourceBergens earnings. The lowest sales estimate is $58.37 billion and the highest is $60.24 billion. AmerisourceBergen posted sales of $52.52 billion during the same quarter last year, which suggests []

Mattern Capital Management LLC raised its stake in AmerisourceBergen Co. (NYSE:ABC) by 0.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 54,574 shares of the company’s stock after buying an additional 433 shares during the quarter. AmerisourceBergen makes up approximately 1.3% of Mattern Capital Management LLC’s portfolio, making the stock its 27th biggest […]

AmerisourceBergen (NYSE:ABC) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Earnings & Valuation This table compares AmerisourceBergen and Chugai Pharmaceuticals revenue, earnings per share and valuation. Gross []

Equities research analysts expect AmerisourceBergen Co. (NYSE:ABC) to report sales of $59.31 billion for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for AmerisourceBergens earnings. The lowest sales estimate is $58.37 billion and the highest is $60.24 billion. AmerisourceBergen posted sales of $52.52 billion during the same quarter last []

Stocks Analysis by Zacks Investment Research covering: AmerisourceBergen, Amphastar P. Read Zacks Investment Research''s latest article on Investing.com

Here is how AmerisourceBergen (ABC) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Here is how AmerisourceBergen (ABC) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Meritage Portfolio Management lifted its position in shares of AmerisourceBergen Co. (NYSE:ABC) by 1.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 48,830 shares of the companys stock after acquiring an additional 501 shares during the period. Meritage Portfolio Managements holdings in AmerisourceBergen were worth $5,833,000 as []

AmerisourceBergen Corporation found using ticker (ABC) now have 13 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 170 and 125 and has a mean target at 144.08. With the stocks previous close at 121.69 this would imply there is a potential upside of 18.4%. There is a 50 day moving average of 121.63 and the 200 day moving average is 119.34. The company has a market capitalisation of $25,627m. Find out more information at: https://www.amerisourcebergen.com [stock_market_widget type="chart" symbol="ABC" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers.